Amarin investors know by now that the big news for the company will be whether its drug Vascepa gets new chemical entity, or NCE, status from the FDA, and so far, the wait has been long for an answer. In the meantime, the company is taking other measures to protect its drug from generic competition. Vascepa was just granted its ninth U.S. patent, and Amarin plans to apply for a 10th. In this video, Motley Fool analysts Max Macaluso and David Williamson discuss another factor that can give the company competitive leverage: increasing the number of suppliers it gets Vascepa's active ingredient from.
Free Article
Join Over Half a 1 Million Premium Members And Get More In-Depth Stock Guidance and Research
Is This the Key for Amarin?
By Max Macaluso and Dave Williamson
–
Nov 20, 2012 at 5:39PM
NASDAQ: AMRN
Amarin Plc
Market Cap
$345M
Today's Change
(8.44%) $0.07
Current Price
$0.92
Price as of September 27, 2023, 4:00 p.m. ET
Amarin is looking at new ways to shore up its defenses against generic competition.
David Williamson owns shares of Amarin. Max Macaluso, Ph.D., has no positions in the stocks mentioned above. The Motley Fool owns shares of GlaxoSmithKline. Motley Fool newsletter services recommend GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Motley Fool Investing Philosophy
- #1 Buy 25+ Companies
- #2 Hold Stocks for 5+ Years
- #3 Add New Savings Regularly
- #4 Hold Through Market Volatility
- #5 Let Winners Run
- #6 Target Long-Term Returns
Why do we invest this way? Learn More
Stocks Mentioned
Amarin Plc
AMRN
$0.92
(8.44%)
$0.07
GSK
GSK
$37.04
(-0.64%)
$0.24
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles
Why Amarin Stock Is Sinking Today
Amarin Plc (AMRN) Q1 2023 Earnings Call Transcript
Amarin Plc (AMRN) Q4 2022 Earnings Call Transcript
Why Amarin Stock Tumbled This Week
Why Amarin Stock Was a Winner Today
459%
Motley Fool Returns
Market-beating stocks from our award-winning analyst team.
Stock Advisor Returns
459%
S&P 500 Returns
124%
Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/28/2023.
Discounted offers are only available to new members. Stock Advisor list price is $199 per year.
Cumulative Growth of a $10,000 Investment in Stock Advisor
Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.